New data released by BrainStorm Cell Therapeutics has revealed promising results for their ALS treatment, NurOwn. The Phase 3 trial showcased a significant reduction in the neurodegeneration biomarker, NfL, among participants who received NurOwn compared to those who were given a placebo.
The decision to analyze biomarker data was influenced by recent FDA approvals for ALS drugs and the correlation between NfL levels and disease prognosis in patients with ALS and other neurodegenerative conditions. This study further confirmed that lower plasma NfL levels are likely indicative of improved clinical outcomes for individuals with ALS.
Stacy Lindborg, PhD, co-CEO of BrainStorm, stressed the importance of examining biomarker data, particularly NfL levels, as a means of predicting disease progression and enhancing clinical outcomes for those with ALS.